Which has preferable earnings & valuation, KYTX or ENGN?

Kyverna Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A enGene N/A N/A -$117.30M -$2.17 N/A

Is KYTX or ENGN more profitable?

enGene's return on equity of -56.06% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% enGene N/A -56.06% -45.64%

Does the media prefer KYTX or ENGN?

In the previous week, enGene had 4 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 7 mentions for enGene and 3 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.56 beat enGene's score of -0.30 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, BNTC or ENGN?

Benitec Biopharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Benitec Biopharma N/A N/A -$37.92M -$1.14 N/A enGene N/A N/A -$117.30M -$2.17 N/A

Is BNTC or ENGN more profitable?

Benitec Biopharma's return on equity of -34.82% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets Benitec Biopharma N/A -34.82% -34.11% enGene N/A -56.06% -45.64%

Is ENGN or PRTA more profitable?

enGene has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Prothena -80.68% -16.45% -14.51%

Does the media favor ENGN or PRTA?

In the previous week, enGene and enGene both had 7 articles in the media. Prothena's average media sentiment score of 0.35 beat enGene's score of -0.30 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Prothena 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is CBIO or ENGN more profitable?

enGene's return on equity of -56.06% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Crescent Biopharma N/A -101.50% -86.86% enGene N/A -56.06% -45.64%

Does the media prefer CBIO or ENGN?

In the previous week, Crescent Biopharma had 3 more articles in the media than enGene. MarketBeat recorded 10 mentions for Crescent Biopharma and 7 mentions for enGene. Crescent Biopharma's average media sentiment score of 0.13 beat enGene's score of -0.30 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral enGene 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings and valuation, CABA or ENGN?

Cabaletta Bio is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.96 N/A enGene N/A N/A -$117.30M -$2.17 N/A

Is CABA or ENGN more profitable?

enGene's return on equity of -56.06% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -131.58% -96.46% enGene N/A -56.06% -45.64%

Does the media refer more to CABA or ENGN?

In the previous week, enGene had 6 more articles in the media than Cabaletta Bio. MarketBeat recorded 7 mentions for enGene and 1 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.67 beat enGene's score of -0.30 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive enGene 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

enGene (ENGN) Competitors

$1.75 -0.05 (-2.78%)

As of 04:00 PM Eastern

Compare

ENGN vs. KYTX, BNTC, PRTA, CBIO, and CABA

Should you buy enGene stock or one of its competitors? enGene's main competitors and comparable companies include Kyverna Therapeutics (KYTX), Benitec Biopharma (BNTC), Prothena (PRTA), Crescent Biopharma (CBIO), and Cabaletta Bio (CABA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does enGene compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Kyverna Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 280.23%. enGene has a consensus target price of $11.05, suggesting a potential upside of 531.17%. Given enGene's higher probable upside, analysts plainly believe enGene is more favorable than Kyverna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, enGene had 4 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 7 mentions for enGene and 3 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.56 beat enGene's score of -0.30 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
enGene	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Kyverna Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

enGene's return on equity of -56.06% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
enGene	N/A	-56.06%	-45.64%

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by company insiders. Comparatively, 10.5% of enGene shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kyverna Therapeutics has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, enGene has a beta of -0.28, indicating that its share price is 128% less volatile than the broader market.

Summary

enGene beats Kyverna Therapeutics on 7 of the 12 factors compared between the two stocks.

How does enGene compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

In the previous week, enGene had 7 more articles in the media than Benitec Biopharma. MarketBeat recorded 7 mentions for enGene and 0 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.00 beat enGene's score of -0.30 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Benitec Biopharma	Neutral
enGene	Neutral

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by insiders. Comparatively, 10.5% of enGene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Benitec Biopharma currently has a consensus target price of $24.80, suggesting a potential upside of 79.97%. enGene has a consensus target price of $11.05, suggesting a potential upside of 531.17%. Given enGene's higher possible upside, analysts plainly believe enGene is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Benitec Biopharma's return on equity of -34.82% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
enGene	N/A	-56.06%	-45.64%

Benitec Biopharma has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, enGene has a beta of -0.28, suggesting that its stock price is 128% less volatile than the broader market.

Benitec Biopharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

Summary

Benitec Biopharma beats enGene on 8 of the 12 factors compared between the two stocks.

How does enGene compare to Prothena?

enGene (NASDAQ:ENGN) and Prothena (NASDAQ:PRTA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

enGene currently has a consensus target price of $11.05, suggesting a potential upside of 531.17%. Prothena has a consensus target price of $23.75, suggesting a potential upside of 160.42%. Given enGene's higher probable upside, equities analysts plainly believe enGene is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, enGene and enGene both had 7 articles in the media. Prothena's average media sentiment score of 0.35 beat enGene's score of -0.30 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

enGene has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Prothena	-80.68%	-16.45%	-14.51%

enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, Prothena has a beta of -0.29, suggesting that its share price is 129% less volatile than the broader market.

enGene has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Prothena	$9.68M	49.32	-$244.09M	-$0.84	N/A

64.2% of enGene shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 10.5% of enGene shares are owned by company insiders. Comparatively, 10.4% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Prothena beats enGene on 9 of the 14 factors compared between the two stocks.

How does enGene compare to Crescent Biopharma?

Crescent Biopharma (NASDAQ:CBIO) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, Crescent Biopharma had 3 more articles in the media than enGene. MarketBeat recorded 10 mentions for Crescent Biopharma and 7 mentions for enGene. Crescent Biopharma's average media sentiment score of 0.13 beat enGene's score of -0.30 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
enGene	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

enGene has lower revenue, but higher earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	59.38	-$153.94M	-$6.72	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

Crescent Biopharma has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, enGene has a beta of -0.28, indicating that its stock price is 128% less volatile than the broader market.

75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 24.8% of Crescent Biopharma shares are owned by company insiders. Comparatively, 10.5% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Crescent Biopharma presently has a consensus target price of $29.40, suggesting a potential upside of 69.65%. enGene has a consensus target price of $11.05, suggesting a potential upside of 531.17%. Given enGene's higher possible upside, analysts plainly believe enGene is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

enGene's return on equity of -56.06% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
enGene	N/A	-56.06%	-45.64%

Summary

Crescent Biopharma beats enGene on 8 of the 14 factors compared between the two stocks.

How does enGene compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

64.2% of enGene shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by insiders. Comparatively, 10.5% of enGene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

enGene's return on equity of -56.06% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
enGene	N/A	-56.06%	-45.64%

Cabaletta Bio has a beta of 3.3, suggesting that its share price is 230% more volatile than the broader market. Comparatively, enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market.

Cabaletta Bio presently has a consensus price target of $15.50, indicating a potential upside of 453.57%. enGene has a consensus price target of $11.05, indicating a potential upside of 531.17%. Given enGene's higher possible upside, analysts plainly believe enGene is more favorable than Cabaletta Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, enGene had 6 more articles in the media than Cabaletta Bio. MarketBeat recorded 7 mentions for enGene and 1 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.67 beat enGene's score of -0.30 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
enGene	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cabaletta Bio is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

Summary

enGene beats Cabaletta Bio on 7 of the 12 factors compared between the two stocks.

Get enGene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENGN vs. The Competition

Export

Metric	enGene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$120.57M	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	N/A	9.13	269.75	24.74
Price / Sales	N/A	1,274.20	652.34	108.60
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.67	17.66	11.27	6.42
Net Income	-$117.30M	-$13.25M	$3.45B	$347.12M
7 Day Performance	-1.13%	5.36%	3.56%	2.48%
1 Month Performance	-7.89%	-1.74%	-0.58%	-1.04%
1 Year Performance	-52.45%	61.36%	77.52%	23.22%

enGene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENGN enGene	2.9532 of 5 stars	$1.75 -2.8%	$11.05 +531.2%	-51.1%	$120.57M	N/A	N/A	31
KYTX Kyverna Therapeutics	2.1224 of 5 stars	$7.92 +2.1%	$30.00 +279.0%	+145.7%	$479.33M	N/A	N/A	96	News Coverage Upcoming Earnings Gap Up
BNTC Benitec Biopharma	1.3702 of 5 stars	$13.39 +2.0%	$24.80 +85.2%	+15.5%	$460.63M	N/A	N/A	20
PRTA Prothena	2.8625 of 5 stars	$8.79 +2.5%	$23.75 +170.1%	+13.9%	$460.39M	$57.94M	N/A	130	Earnings Report
CBIO Crescent Biopharma	2.405 of 5 stars	$16.61 +1.1%	$29.40 +77.0%	+31.1%	$457.77M	$10.84M	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENGN) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

enGene (ENGN) Competitors

ENGN vs. KYTX, BNTC, PRTA, CBIO, and CABA

How does enGene compare to Kyverna Therapeutics?

Summary

How does enGene compare to Benitec Biopharma?

Summary

How does enGene compare to Prothena?

Summary

How does enGene compare to Crescent Biopharma?

Summary

How does enGene compare to Cabaletta Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN vs. The Competition

enGene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

enGene (ENGN) Competitors

ENGN vs. KYTX, BNTC, PRTA, CBIO, and CABA

How does enGene compare to Kyverna Therapeutics?

Do analysts recommend KYTX or ENGN?

Does the media prefer KYTX or ENGN?

Which has preferable earnings & valuation, KYTX or ENGN?

Is KYTX or ENGN more profitable?

Do institutionals & insiders have more ownership in KYTX or ENGN?

Which has more volatility and risk, KYTX or ENGN?

Summary

How does enGene compare to Benitec Biopharma?

Does the media prefer BNTC or ENGN?

Do insiders & institutionals have more ownership in BNTC or ENGN?

Do analysts recommend BNTC or ENGN?

Is BNTC or ENGN more profitable?

Which has more risk & volatility, BNTC or ENGN?

Which has stronger valuation & earnings, BNTC or ENGN?

Summary

How does enGene compare to Prothena?

Do analysts recommend ENGN or PRTA?

Does the media favor ENGN or PRTA?

Is ENGN or PRTA more profitable?

Which has more volatility and risk, ENGN or PRTA?

Which has higher valuation and earnings, ENGN or PRTA?

Do institutionals & insiders have more ownership in ENGN or PRTA?

Summary

How does enGene compare to Crescent Biopharma?

Does the media prefer CBIO or ENGN?

Which has better valuation and earnings, CBIO or ENGN?

Which has more volatility & risk, CBIO or ENGN?

Do insiders and institutionals have more ownership in CBIO or ENGN?

Do analysts prefer CBIO or ENGN?

Is CBIO or ENGN more profitable?

Summary

How does enGene compare to Cabaletta Bio?

Do insiders & institutionals believe in CABA or ENGN?

Is CABA or ENGN more profitable?

Which has more risk & volatility, CABA or ENGN?

Do analysts recommend CABA or ENGN?

Does the media refer more to CABA or ENGN?

Which has better earnings and valuation, CABA or ENGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN vs. The Competition

enGene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools